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As is the case for most industrialized countries, lung cancer is the
most prevalent form of cancer in the UK. Along with ischaemic
heart disease, cerebrovascular disease and pneumonia, it has
ranked amongst the top four causes of mortality over the past
3 decades (Office of Health Economics, 1997). Although it is
generally believed that lung cancer treatment places a substantial
burden on national health care resources, few data are available to
substantiate this belief (Evans et al, 1995a). This paper presents
estimates of the direct economic costs of the hospital treatment of
lung cancer, based on the records of a sample of patients drawn
from the Trent region (central England).
Most cases of lung cancer present symptomatically, either in
general practice or as emergency hospital admissions. Diagnosis is
usually made on the basis of clinical examination and chest X-ray,
complemented with, for example, bronchoscopy, needle biopsy,
lung function tests, computerized tomography and/or forms of
radioisotope scanning. The majority of lung cancer patients
(typically around 75–80%) are diagnosed with non-small cell lung
cancer (NSCLC) (Report of a meeting of physicians at the Royal
Marsden Hospital, 1995). For them, surgical techniques may prove
appropriate, whilst inoperable patients will be treated with radio-
therapy (Williams, 1992) and, rarely in the UK at present,
chemotherapy. Chemotherapy is the preferred treatment for small
cell lung cancer (SCLC) cases, on occasions in combination with
radiotherapy (Standing Medical Advisory Committee, 1994).
Patients will usually receive post-treatment follow-up involving
X-rays and/or scanning, although practices and policies appear to
vary widely between clinics (Virgo et al, 1996). The majority of
patients will eventually require palliative chemotherapy, palliative
radiotherapy and/or symptom control. This having been said, it is
probable that many patients never receive any treatment for lung
cancer.
MATERIALS AND METHODS
The epidemiology of cancer in the UK has long been documented
by the regional Cancer Registries, although the Registry databases
do not include details of resource use. Our cost estimates were
therefore based on an analysis of treatment records of a sample of
individual patients. Individual patient costing provides far more
realistic overall cost estimates than average costing or simulated
costing. However, by auditing cost-events for each single patient,
the procedure is particularly time-consuming (Whynes and
Walker, 1995). With 3–4000 lung cancer cases being diagnosed
annually in Trent, a complete cost analysis of a full year’s cohort
was deemed to be prohibitively expensive. Accordingly, we
identified an approximately 1-in-10, random sample of 300 cancer
patients from the Trent register. All had been nominally diagnosed
with lung cancer in 1993. We selected the particular year as a
baseline on the grounds that it would permit us to construct a
resource audit for each patient for up to 4 years, a period following
diagnosis during which the majority of cancer recurrences and
treatment complications would be likely to occur. An attempt to
retrieve the full treatment records of these cases revealed that, for
47 patients, notes were untraceable, or cancers had been mis-
classified, either by diagnosis or by year. After these exclusions,
253 records were available for analysis.
A full audit of resource-using hospital events was compiled for
each of these patients, for 4 years following initial diagnosis or
until death, if occurring earlier. The unit costs of these events were
obtained from a survey of 11 of the region’s principal service
providers, each of whom was sent a form requesting the cost of
the various activities, as performed at their site. Since 1993, all
National Health Service (NHS) providers have been required to
follow a uniform accounting protocol, requiring that their services
be costed at full cost, i.e. all service-specific variable costs, with
the inclusion of the relevant components of fixed and overhead
costs (NHS Management Executive, 1993). We employed the
mean of the reported costs of each event in our estimates,
converted back to 1993 prices using the NHS pay and price index.
Given that management events were occurring across time, the
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were discounted at 6%. In other words, mean 4-year costs were
expressed as a 1993 present value, to represent the prospective
cost implications from the perspective of the baseline year. The
discount rate chosen was that conventionally employed in evalua-
tions of UK public sector projects (Parsonage and Neuberger,
1992).
RESULTS
Of the random sample selected for analysis, approximately 10% of
cases (26/253) were diagnosed as SCLC. The mean/median age
at diagnosis of the samples of patients was 71/72 years [standard
deviation (s.d.) 9, range 35 years] for NSCLC, and 66/67 years
(s.d. 9, range 47 years) for SCLC. Considerable diversity with
respect to cost-events was evident on a patient-by-patient basis.
For example, a total of 19 distinct diagnostic events were found to
have occurred amongst the sample as a whole, and in a wide
variety of combinations. Table 1 displays data on the frequency of
use of investigations and treatments for the first year of diagnosis
and treatment only, together with mean unit costs derived from
the provider survey. Surgery included thoracotomy, lobectomy,
segmentectomy and pneumonectomy. In most cases, many or all
of the diagnostic events were undertaken on an in-patient basis
although, in others, some of the tests were administered on an out-
patient or day-case basis, with differential consequences for costs.
Table 2 displays data pertaining to usage of in-patient care over the
entire 4-year period. On the basis of our provider survey, the mean
overhead cost of in-patient care amounted to £186.20 per day. Our
estimate for in-patient palliative care comprises only hospital care
for palliation related directly to lung cancer and associated events,
for example, metastases.
Patient-specific radiotherapy costs varied with type (palliative
or radical, low energy or simple), number of fractions and setting
(e.g. in-patient or out-patient), with mean costs per episode being
within a very wide range, £290–6650. Within the sample, seven
different chemotherapy drugs were employed, in combinations,
dosages and settings specific to each of the patients so treated.
Again, unit drug costs were highly variable; for example, cisplatin
at £0.5 per ml, methotrexate at £1 per ml and mitomycin at £2 per
mg (all approximate). After primary treatment, each patient
received one or more of up to 13 forms of immediate procedure or
follow-up investigation, largely the same as those used as initial
investigations (Table 1). Twenty per cent of NSCLC, and 23%
of SCLC, patients required further in-patient stays, including
emergency admission, surveillance for metastases, spinal cord
compression, pleural effusion and blood transfusion.
In consequence of the great diversity in patient management
routes, the cost audits of patient-specific events rapidly assumed
great complexity. Space precludes a full exposition of the patient-
specific cost algorithms developed, although these are available
from the authors on request.
Table 3 displays the mean 4-year costs by broad management
category. Costs associated with in-patient episodes accounted for
80% and 76% of mean costs for NSCLC and SCLC respectively.
Only 14 patients (6%) survived the full 4 years following
diagnosis and, on average, 96% and 97% of all costs were incurred
in the first year in the two sub-samples respectively. In con-
sequence, the cost estimates were extremely insensitive to
variations in the discount rate. It is evident from Table 3 that, for
both the cost totals and the majority of management categories, the
means exceeds the medians, implying distributional skews to the
right. Evidently, a small numbers of patients generated dispropor-
tionately high costs, a conclusion supported by the high value for
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Table 1 Utilization of services and unit costs during first year following diagnosis
Non-small cell (n = 227) Small cell (n = 26)
Number % Number % Unit costs (£)
Diagnosis and initial investigations
Chest X-ray 215 94.7 26 100.0 11.5
Blood count 205 90.3 23 88.5 3.3
Liver function test 143 63.0 16 61.5 6.6
Bronchoscopy 128 56.4 18 69.2 308.4
Lung function test 112 49.3 7 26.9 79.8
CT scan 97 42.7 12 46.2 94.3
Biopsy (lung) 94 41.4 – – 42.3
Sputum cytology 67 29.5 9 34.6 13.7
Ultrasound 43 18.9 9 34.6 27.9
Other X-ray 27 11.9 2 7.7 21.4
Bone scan 21 9.3 3 11.5 77.0
Pleural aspiration 19 8.4 3 11.5 45.0
Percutaneous needle biopsy 15 6.6 1 3.8 67.9
Fine needle aspiration 13 5.7 – – 43.1
Biopsy (lymph node) 8 3.5 4 15.4 42.3
Biopsy (pleural) 8 3.5 1 3.8 42.3
Mediastinoscopy 4 1.8 – – 239.5 per day
MRI scan 3 1.3 1 3.8 163.6
Bone marrow aspiration 2 0.9 1 3.8 45.0
Treatment
Inpatient palliative care 92 40.5 10 38.5 231.6 per day
Palliative radiotherapy 79 34.8 13 50.0 see text
Surgery 17 7.5 – – 382.1 per day
Radical radiotherapy 9 4.0 2 7.7 see text
Chemotherapy 4 1.8 15 57.7 see textthe range in some categories. Differences in both the mean and the
median costs of the two lung cancer types were insignificant
(Mann–Whitney test).
Patients’ smoking histories should be routinely recorded in
medical notes. Those recorded as being regular tobacco smokers
at the time of admission constituted 43% of the sample. However,
the mean 4-year management costs of this cohort did not differ
significantly from those of non-smokers, those who had been
recorded as never having smoked or having ceased smoking for at
least 6 months prior to diagnosis.
DISCUSSION
To date, the most ambitious attempt to cost lung cancer manage-
ment has taken place in Canada (Rafuse, 1993; Evans et al, 1995a,
1995b, 1996). This research produced 5-year cost estimates of
£10–15 000 for NSCLC and of £15–19 000 for SCLC (converted
to sterling 1993, using the exchange rate and the NHS pay and
price index). These estimates are considerably higher than those
identified in our study, although the transparency of the Canadian
research allows us to identify the sources of the discrepancies.
First, the assumed per diem cost of in-patient stay was almost
twice as high in the Canadian study as it was in the Trent analysis.
This presumably reflects on the different financial structures of the
two health care systems and, as noted above, in-patient costs are a
major component of overall management costs. Second, the
methodology of the studies differs. The Canadian estimates have
not been obtained solely from direct observation of patient experi-
ences. They are based on simulations or models of events, derived
both from agreed clinical protocols and from specialist opinion on
the nature of ‘proper practice’. In particular, the Canadian pro-
tocols appeared to have allowed for more radical treatments than
was observed in our sample and the authors accepted that such an
assumption might have been unrealistic in the case of elderly, frail
patients. For example, over 85% of Canadian NSCLC patients
were deemed eligible for surgical resection, with an average
hospital stay of 20 days. In our sample, only 8% of NSCLC
patients received resection, with an average stay of 14 days. Third,
the Canadian study reported 5-year survival following diagnosis of
all forms of lung cancer at 13%, superior to the observed 4-year
rate for Trent. The proportion of costs incurred by the Canadian
patients in the first year were 82% and 83% for NSCLC and SCLC
respectively. These results are consistent with the view that the
Trent patients received less aggressive therapy than was assumed
to be the case for the Canadian patients.
The treatment costs of lung cancer may be compared directly
with the equivalent costs estimated for two other sites. Mean
4-year costs for breast cancer treatment have been estimated at
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Table 2 Length of in-patient stay (days)
Non-small cell Small cell
Patients receiving: for which: Patients receiving: for which:
Number % Mean s.d. Number % Mean s.d.
Diagnosis 168 74.0 13.1 15.0 20 76.9 11.2 8.6
Surgery 17 7.5 13.7 6.3 0 – – –
Radical radiotherapy 3 1.3 14.7 9.1 0 – – –
Chemotherapy 3 1.3 4.0 2.0 5 19.2 15.4 9.2
Palliative radiotherapy 18 7.9 13.2 16.8 0 – – –
Inpatient palliative care 104 45.8 25.1 48.3 11 42.3 13.7 11.3
Further investigations 44 19.4 12.5 12.9 6 23.1 6.3 5.6
Table 3 Four-year costs of lung cancer diagnosis, treatment and follow-up (£ in 1993)
Patients receiving: for which: Distribution at:
Number % Mean 25% 50% 75% Range
Non-small cell
Diagnosis 227 100.0 2954 555 1673 4667 28 695
Surgery 17 7.5 5230 3248 5350 6878 8025
Radical radiotherapy 10 4.4 4345 634 2444 11 029 10 947
Chemotherapy 4 1.8 945 319 719 1797 1733
Palliative radiotherapy 82 36.1 727 77 291 772 6581
Inpatient palliative care 93 41.0 3962 559 1862 3723 67 952
Further investigations 44 19.4 2958 1117 2048 4448 10 989
Follow-up 120 52.9 387 105 252 472 2824
Total 227 100.0 6150 1713 4132 8399 78 100
Small cell
Diagnosis 26 100.0 2746 552 2287 4072 8585
Surgery 0 0.0 – – – – –
Radical radiotherapy 2 7.7 531 81 531 – 899
Chemotherapy 15 57.7 1558 100 381 2351 5707
Palliative radiotherapy 14 53.8 317 77 214 521 695
Inpatient palliative care 10 38.5 2649 1024 2445 3444 7633
Further investigations 6 23.1 2264 465 1582 3909 6513
Follow-up 17 65.4 414 114 280 671 1266
Total 26 100.0 5668 1810 4078 10 917 13 513£3–4000 for stages 1 to 3, but at approximately £6600 for stage 4
(Wolstenholme et al, 1998). Mean 5-year costs for cervical cancer
management have been estimated at around £6600 for
stage 1, but at £11–12 000 for stages 2 to 4 (Wolstenholme and
Whynes, 1998). These three cost results are comparable as each of
the studies concerned used the same estimation methods. As with
the lung cancer case, the preponderance of resource use in both
breast and cervical cancer occurred in the year immediately
following diagnosis. These data suggest that the treatment costs of
lung cancer are not disproportionately higher than for those for
cancers at other sites.
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